These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14743588)

  • 1. Provider boycotts--a review of the Merck-Medco decision. Merck-Medco Managed Care L.L.C. v. Rite Aid Corporation.
    Becker S
    Health Care Law Mon; 2000 May; ():10-8. PubMed ID: 14743588
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 3. Implications for managed care organizations of the Merck and Medco consent.
    Pollard MR; Tilson HH
    Med Interface; 1996 Mar; 9(3):60-2. PubMed ID: 10184511
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacies take uniform price demands to court.
    Moskowitz DB
    J Am Health Policy; 1994; 4(4):24-7. PubMed ID: 10136676
    [No Abstract]   [Full Text] [Related]  

  • 5. State and federal government mandates are changing the face of pharmacy management.
    Giaquinta D
    Manag Care Interface; 2001 May; 14(5):50-2. PubMed ID: 11385948
    [No Abstract]   [Full Text] [Related]  

  • 6. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
    Whitener MD
    Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
    [No Abstract]   [Full Text] [Related]  

  • 7. A whole new world?: pharmaceutical responses to the managed care revolution.
    Balto DA
    Food Drug Law J; 1997; 52(1):83-98. PubMed ID: 10346712
    [No Abstract]   [Full Text] [Related]  

  • 8. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 9. The evolving role of pharmacy benefits management firms in a managed care environment.
    O'Leary JS
    Benefits Q; 1995; 11(3):24-33. PubMed ID: 10151118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
    [No Abstract]   [Full Text] [Related]  

  • 11. Finance issue brief: any willing provider: year end report-2002.
    Morgan R; MacEachern L
    Issue Brief Health Policy Track Serv; 2002 Dec; ():1-10. PubMed ID: 12884878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs.
    Food Drug Law J; 1998; 53(1):25-34. PubMed ID: 11795334
    [No Abstract]   [Full Text] [Related]  

  • 13. How well does your PBM perform?
    McCarthy R
    Bus Health; 1999 Jan; 17(1):24-9. PubMed ID: 10345211
    [No Abstract]   [Full Text] [Related]  

  • 14. Capitation risks for pharmacy services.
    Navarro RP
    Med Interface; 1994 Jul; 7(7):88-90. PubMed ID: 10135996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Judge Posner's RFP: antitrust law and managed care.
    Sage WM
    Health Aff (Millwood); 1997; 16(6):44-61. PubMed ID: 9444808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 17. States on the Front Line: Addressing America's Drug Pricing Problem.
    Riley T; Lanford S
    J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
    [No Abstract]   [Full Text] [Related]  

  • 18. Meeting resistance. Express Scripts-Medco deal called anti-competitive.
    Lee J
    Mod Healthc; 2011 Aug; 41(32):10-1. PubMed ID: 21879692
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical pricing. Let the market decide who gets discounts.
    Mossinghoff GJ
    Health Syst Rev; 1995; 28(1):24-5. PubMed ID: 10139754
    [No Abstract]   [Full Text] [Related]  

  • 20. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.